Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323/DB-1303 vs Chemotherapy in Previously Treated HER2-Expressing Recurrent Endometrial Cancer
NCT06340568Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 27
01
Overview
A Phase 3 trial of trastuzumab pamirtecan in endometrial cancer (EC), sponsored by BioNTech SE. Started Jun 2025; status: recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06340568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340568.